FDA approves Teva's generic Effexor XR antidepressant

Download PDF Copy

Jun 29 2010

Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) announced today U.S. Food and Drug Administration (FDA) approval of Venlafaxine HCl ER Capsules, the Company's generic version of Wyeth's antidepressant Effexor XR®. Shipment is expected to commence on July 1, 2010, as per the terms of the 2006 agreement with Wyeth.

As the first company to file an Abbreviated New Drug Application (ANDA) containing a paragraph IV certification for this product, Teva has been awarded a 180-day period of marketing exclusivity.

The brand product had annual sales of approximately $2.75 billion in the United States, based on IMS sales data.

Source:

Teva Pharmaceutical Industries Ltd.,

Posted in: Medical Condition News | Pharmaceutical News

Comments (0)

Download PDF Copy

Suggested Reading

Brightly colored food and drinks hide synthetic dyes and lots of sugar

Scientists set out to map the world’s traditional food environments and their health impacts

How ‘free from’ and ‘organic’ claims dominate baby food marketing in NZ

Are all healthy diets equal or does food processing make a difference?

CURE GABA-A and Grann Pharmaceuticals announce global partnership to advance rare neurological therapies

Food scientists identify worst additives for longevity: flavours, sweeteners, and colourings top list

Seattle’s Fresh Bucks program boosts food security and diet but benefits fade when funding ends

Food insecurity raises long COVID risk while SNAP support cuts it

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.